Although it is unknown whether T-LICs are positive or negative for CD38, blasts from patients with T-ALL have robust surface expression of CD38 at the time of diagnosis, 1 month post induction, and relapse, making it an ideal target for T-ALL patients who relapse or do not respond to conventional chemotherapies [171,172]. Here, CD38 is linked to acute lymphoblastic leukemia.